2/18
08:00 am
lpcn
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Low
Report
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
2/15
01:09 am
lpcn
Medium
Report
2/11
03:28 pm
lpcn
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 [Yahoo! Finance]
Low
Report
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 [Yahoo! Finance]
1/21
07:17 am
lpcn
Lipocine (NASDAQ:LPCN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Lipocine (NASDAQ:LPCN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/20
08:00 am
lpcn
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Medium
Report
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
1/12
08:32 am
lpcn
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
High
Report
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
1/12
08:00 am
lpcn
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
High
Report
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
12/16
08:27 am
lpcn
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone [Yahoo! Finance]
Neutral
Report
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone [Yahoo! Finance]
12/16
08:00 am
lpcn
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Low
Report
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
12/9
04:25 pm
lpcn
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
01:53 pm
lpcn
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.